Liquid‐based gynecologic cytology is being implemented in U.S. laboratories within a complex business, marketing, and scientific environment. Although increased detection of squamous intraepithelial lesions appears promising in early direct‐to‐vial studies, further risk management experience is needed with the new technology, particularly with regard to the detection of clinically significant endocervical glandular lesions and adequacy criteria.
See also pages 202‐7.